Neal Edward Ready, MD, PhD

Professor of Medicine
Member of the Duke Cancer Institute
Campus mail 25178 Morris Bldg-200 Trent Dr., Box 3198, Durham, NC 27710
Phone (919) 681-6932
Email address neal.ready@duke.edu

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Tufts University, 1992 - 1994
  • Fellow in Hematology-Oncology, Medicine, Brown University, 1990 - 1992
  • Medical Resident, Medicine, Brown University, 1986 - 1989
  • M.D., Vanderbilt University, 1986
  • Ph.D., University of California at Irvine, 1983

Publications

Yang, C-FJ, McSherry, F, Mayne, NR, Wang, X, Berry, MF, Tong, B, Harpole, DH, D'Amico, TA, Christensen, JD, Ready, NE, and Klapper, JA. "Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small-Cell Lung Cancer." The Annals of thoracic surgery (December 16, 2017).

PMID
29258674
Full Text

Yi, JS, Ready, N, Healy, P, Dumbauld, C, Osborne, R, Berry, M, Shoemaker, D, Clarke, J, Crawford, J, Tong, B, Harpole, D, D'Amico, TA, McSherry, F, Dunphy, F, McCall, SJ, Christensen, JD, Wang, X, and Weinhold, KJ. "Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab." Clinical cancer research : an official journal of the American Association for Cancer Research 23, no. 24 (December 2017): 7474-7482.

PMID
28951518
Full Text

Faries, MB, Mozzillo, N, Kashani-Sabet, M, Thompson, JF, Kelley, MC, DeConti, RC, Lee, JE, Huth, JF, Wagner, J, Dalgleish, A, Pertschuk, D, Nardo, C, Stern, S, Elashoff, R, Gammon, G, and Morton, DL. "Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases." Annals of Surgical Oncology 24, no. 13 (December 2017): 3991-4000.

Full Text

Horn, L, Spigel, DR, Vokes, EE, Holgado, E, Ready, N, Steins, M, Poddubskaya, E, Borghaei, H, Felip, E, Paz-Ares, L, Pluzanski, A, Reckamp, KL, Burgio, MA, Kohlhäeufl, M, Waterhouse, D, Barlesi, F, Antonia, S, Arrieta, O, Fayette, J, Crinò, L, Rizvi, N, Reck, M, Hellmann, MD, Geese, WJ, Li, A, Blackwood-Chirchir, A, Healey, D, Brahmer, J, and Eberhardt, WEE. "Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 35 (December 2017): 3924-3933.

PMID
29023213
Full Text

Stinchcombe, TE, Zhang, Y, Vokes, EE, Schiller, JH, Bradley, JD, Kelly, K, Curran, WJ, Schild, SE, Movsas, B, Clamon, G, Govindan, R, Blumenschein, GR, Socinski, MA, Ready, NE, Akerley, WL, Cohen, HJ, Pang, HH, and Wang, X. "Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 35, no. 25 (September 2017): 2885-2892.

PMID
28493811
Full Text

Tandberg, DJ, Kelsey, CR, D'Amico, TA, Crawford, J, Chino, JP, Tong, BC, Ready, NE, and Wright, A. "Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall." Clinical lung cancer 18, no. 4 (July 2017): e259-e265.

PMID
27965012
Full Text

Zhou, F, Wang, Y, Liu, H, Ready, N, Han, Y, Hung, RJ, Brhane, Y, McLaughlin, J, Brennan, P, Bickeböller, H, Rosenberger, A, Houlston, RS, Caporaso, N, Landi, MT, Brüske, I, Risch, A, Ye, Y, Wu, X, Christiani, DC, Goodman, G, Chen, C, Transdisciplinary Research in Cancer of the Lung (TRICL) Research Team, , Amos, CI, and Wei, Q. "Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs." Molecular carcinogenesis 56, no. 4 (April 2017): 1227-1238.

PMID
27805284
Full Text

Kelley, MJ, Jha, G, Shoemaker, D, Herndon, JE, Gu, L, Barry, WT, Crawford, J, and Ready, N. "Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer." Cancer investigation 35, no. 1 (January 2017): 32-35.

PMID
27911119
Full Text

Rudin, CM, Pietanza, MC, Bauer, TM, Ready, N, Morgensztern, D, Glisson, BS, Byers, LA, Johnson, ML, Burris, HA, Robert, F, Han, TH, Bheddah, S, Theiss, N, Watson, S, Mathur, D, Vennapusa, B, Zayed, H, Lally, S, Strickland, DK, Govindan, R, Dylla, SJ, Peng, SL, Spigel, DR, and SCRX16-001 investigators, . "Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study." The Lancet. Oncology 18, no. 1 (January 2017): 42-51.

PMID
27932068
Full Text

Ryser, MD, Lee, WT, Ready, NE, Leder, KZ, and Foo, J. "Quantifying the Dynamics of Field Cancerization in Tobacco-Related Head and Neck Cancer: A Multiscale Modeling Approach." Cancer research 76, no. 24 (December 2016): 7078-7088.

PMID
27913438
Full Text

Pages